Rapport Therapeutics’ Lock-Up Period To End on December 4th (NASDAQ:RAPP)

Rapport Therapeutics’ (NASDAQ:RAPP) lock-up period will end on Wednesday, December 4th. Rapport Therapeutics had issued 8,000,000 shares in its initial public offering on June 7th. The total size of the offering was $136,000,000 based on an initial share price of $17.00. After the end of the company’s lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Rapport Therapeutics Trading Up 0.2 %

Shares of NASDAQ RAPP opened at $22.39 on Friday. The business has a 50 day simple moving average of $23.09. Rapport Therapeutics has a twelve month low of $16.55 and a twelve month high of $29.74.

Institutional Trading of Rapport Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC raised its position in shares of Rapport Therapeutics by 10.1% in the third quarter. FMR LLC now owns 5,486,468 shares of the company’s stock worth $112,363,000 after buying an additional 503,117 shares in the last quarter. ARCH Venture Management LLC purchased a new stake in shares of Rapport Therapeutics in the 2nd quarter valued at about $86,730,000. Johnson & Johnson bought a new stake in shares of Rapport Therapeutics during the 2nd quarter valued at about $58,105,000. Sofinnova Investments Inc. bought a new stake in shares of Rapport Therapeutics during the 2nd quarter valued at about $45,393,000. Finally, Perceptive Advisors LLC purchased a new position in shares of Rapport Therapeutics during the second quarter worth about $17,403,000.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.